Drug discovery often begins with target identification. Candidate therapies such as small molecules or biologics will interact with a target and interfere with a specific disease mechanism. These candidates and their targets are identified through the drug discovery and development process only with innovation, scientific rationale, and considerable intellectual input. To assist our clients in this complex course, we provide engaged, highly competent study directors and staff with diverse research-intensive backgrounds that are focused on understanding and meeting your study objectives!
Buffalo BioLabs offers services in the following areas of drug development:
Buffalo BioLabs (BBL) specializes in preclinical animal studies, analytical studies, as well as in identification/validation of novel pharmacological targets and discovery and preclinical development of drugs that effectively interact with these targets.
Our extensive experience has been primarily concentrated in the fields of cancer, age-related diseases, radiation pathologies, immunological disorders and infectious diseases, yet it is fully applicable to other fields or types of diseases.
The expertise of our research team, which is both broad and deep, has led to successful execution of numerous IND-enabling mechanistic and efficacy studies in a variety of in vitro and in vivo models. We offer a comprehensive range of research services focused on driving drug development from the earliest stages of discovery through advanced preclinical development.
These services include development and validation of experimental models and assays and full characterization of novel drugs, spanning both conventional (e.g., efficacy, pharmacology, PK/PD, toxicity, metabolism) and аdvanced (e.g., systemic effects/side effects, molecular mechanisms, biomarker discovery and validation, target identification) aspects of drug development.
BBL’s success in these types of studies stems from the team’s access to and experience with a rich, customizable research tool set, including:
- Cell-based readout and screening systems
- Immunological and other bioanalytical assays
- Clinically relevant animal models of diseases and therapies